Lab tests

All Tests

Cancer Tests

Cancer patients can use a number of laboratory tests to help them make more informed decisions about treatment choices, monitor treatment progress, predict recurrence risk and so on. Some of these may be available from your own doctor or cancer treatment centre.

Please note:
1. cancerireland.ie does NOT benefit in any way from the inclusion of goods or service listed on the site.
2. The list of laboratories is not complete. It is updated periodically.


Thermography: Early Breast Cancer Detection Test

While breast cancer can only be truly diagnosed by tissue biopsy, breast thermography safely eliminates the need for most unnecessary biopsies as well as the associated emotional suffering, and it does so years sooner than any other test in modern medicine.

Learn more

It uses an infrared camera with a highly accurate heat sensor to detect differences in temperature in the body. The body’s temperature is displayed graphically in different colours on a screen. Normally, the body’s temperature is symmetrical but abnormalities, injuries and pathologies change the temperature of the surrounding tissue and these differences are clearly visible on the scan.

Can DITI diagnose cancer?
Thermal Imaging, mammography and ultrasound are all methods to investigate human physiology and human anatomy. Digital Infrared Thermal Imaging is a screening service that measures skin surface temperature to a very sensitive and accurate degree reflecting changes in physiological and metabolic activity within the underlying tissue area.

While breast cancer can only be truly diagnosed by tissue biopsy, breast thermography safely eliminates the need for most unnecessary biopsies as well as the associated emotional suffering, and it does so years sooner than any other test in modern medicine. Source: Trinity Chiropractic & Natural Health Centre

Where can I get this test?
This test is now available at numerous medical facilities including:
Trinity Chiropractic & Natural Health Centre Ireland
Hollywood Health (Northern Ireland)
Breast Thermography (USA – list of testing centers country-wide)


Tests to Detect Cancer Early

Early detection will give you lots of time to change your diet and lifestyle before the condition has time to develop into full blown cancer.

Learn more

Oncotrace
Test is available from: R.G.C.C Group
Europe: email: info@rgcc-europe-nw.com
USA and Canada: email: info@rgccusa.com

This test will report the number of Circulating Tumor Cells and any positive Circulating Cancer Stem Cells, and the immunophenotype of these cells.

Circulating Tumour Cells
CTCs are cancer cells which have broken away from the primary tumor and have entered the blood stream where they circulate and have the potential to generate metastatic disease. These cells can be isolated and identified and there is growing interest in their detection for the following purposes.

1. The early detection and diagnosis of new cancers
Monitoring existing cancers
Prognosis – providing information about the risk of recurrence of a current or old cancer

R.G.C.C. Group offers general assays for CTCs and for specific cancers, including breast, colorectal, prostate, malignant melanoma and sarcomas.

Source: R.G.C.C Group


CellSearch ®
Test available from: Menarini Silicon Biosystems (Europe and USA)

New method for measuring circulating tumor cells in blood.
The test identifies and counts the number of circulating tumor cells, down to 1 cell, and from an ordinary 7.5 ml blood sample. The cut off limit is 5, so if the patient has less than 5 CTCs the prognosis is far better than if the number is above.

By a cell count over 5, the goal of proper treatment is to lower the count to below 5, which substantially improves the prognosis. Is the number under 5, the doctors will probably choose a milder and less toxic treatment, and can thus save the patient from severe side effects.

With the CTC test it is possible, after as early as 3 weeks, to see if a given treatment works. If not, it can be stopped immediately and replaced by another type of treatment. This saves valuable time by avoiding unnecessary treatment often associated with many side effects, and the CTC test is capable, much better than previously, of predicting a specific prognosis.
Article source: Humlegaarden


Nagalase Blood Test
Test available from: European Laboratory of Nutrients
The Netherlands.
Nagalase in blood is a sensitive test for monitoring the effect of the therapy in patiënts with cancer and certain viral infections, including HIV. Because of the short half-life of nagalase the method is suitable for monitoring various types of therapy. The great sensitivity of the test will help the physician / oncologist to obtain a better understanding of the therapy and to fine-tune the treatment.
Source: European Laboratory of Nutrients


ONCOblot® Test
Test available from : Oncoblot Labs (USA)
info@oncoblotlabs.com

The ONCOblot® blood test identifies a specific type of protein in the blood, ENOX2, which exists only on the surface of a malignant cancer cell. The ENOX2 proteins are shed into the circulation and can be detected in the blood. These proteins serve as highly sensitive markers for confirmation of cancer presence. The test is a valuable complement to early intervention.

How sensitive is the cancer blood test?
The ONCOblot® Test has been shown to detect cancer as early as Stage 0. The limit of detection is an estimated 2 million cells (2 mm or less tumor mass, roughly the size of a pinhead) compared to several billion cells for a positive mammogram. Article source: Oncoblot Labs


The CA Profile Plus©
Test available from: American Metabolic Laboratories

The Cancer Profile™© is pre-visual, meaning, unlike CT, MRI, x-ray, other tests, it can pick up developing cancer years before these other methods do. Having this earliest “diagnosis” allows the doctor and the patient to successfully change an improper lifestyle that does lead to cancer. Source: American Metabolic Laboratories


HCG Urine Immunoassay
Test available from: Navarro Medical Clinic

Developed in the late 1950s, by the renowned oncologist, the late Dr. Manuel D. Navarro, the test detects the presence of cancer cells even before signs or symptoms develop. Dr. Navarro found HCG to be present in all types of cancers. The test is based on a theory proposed by Howard Beard and other researchers who contend that cancer is related to a misplaced trophoblastic cell that become malignant in a manner similar to pregnancy in that they both secrete HCG. As a consequence, a measure of the amount of HCG found in the blood or urine is also a measure of the degree of malignancy. The higher the number, the greater is the severity of cancer.

Urine, as opposed to blood or serum, is the preferred specimen for the test.
The test detects the presence of brain cancer as early as early as 29 months before symptoms appear; 27 months for fibro sarcoma of the abdomen; 24 months for skin cancer; 12 months for cancer of the bones (metastasis from the breast extirpated 2 years earlier).

Currently, many cancer patients take advantage of the diagnostic accuracy of the HCG test as an indicator of the effectiveness of their specific mode of therapy. Thousands of cancer survivors have used this test over the years to keep track of their treatment(s) success and check on the status of their remission. Article source: Navarro Medical Clinic


The AMAS Test
Test available from: Oncolabinc (USA)
Note for patients outside the U.S
In an email reply to cancerireland.ie, Oncolabinc said:
“We will do the AMAS test for European clients, but as stated below, it can be quite difficult. We have a partner in Germany who can run tests for those in Germany and Austria – patients can email us at info@oncolabinc.com requesting that information if they would like.”

Physicians around the country are recommending and administering the AMAS test on a regular basis for patients at high risk for cancer, and for follow-up purposes on patients already diagnosed and/or treated for cancer.

Unlike tests such as CEA, which measure less well-defined antigens whose serum levels tend to be inconstant but elevated late in the disease, the AMAS test measures a well-defined antibody whose serum levels rise early in the course of the disease.

A common clinical situation involves signs or symptoms suggesting a disorder which may or may not be malignant. While neither AMAS nor any other clinical laboratory test can by itself answer this question, AMAS test results may help the physician in the diagnostic process. Article source: Oncolabinc


EarlyCDT®– Lung
Test available from: Oncimmune (List of laboratories offering this test worldwide)

EarlyCDT®Lung is a simple blood test which is ordered by your Doctor to aid in the risk assessment and early detection of lung cancer.

Early in the development of a solid tumour cancer, the body mounts an immune response to certain by-products, or proteins, (tumour antigens) from cancer cells by producing autoantibodies. These autoantobodies which can rise in the earliest stages of cancer, and have been shown to be present at all stages, are produced in sufficient quantities to be measured in an individual’s blood using a simple blood test, EarlyCDTLung.

There is no one type of tumour associated antigen or autoantibody that can be used to detect all or any type of cancer, therefore EarlyCDTLung has been developed to measure a panel of 7 autoantobodies associated specifically with lung cancer.

EarlyCDTLung has been developed so that individuals at moderate or high risk of developing lung cancer can benefit from an increasing chance that lung cancer can be detected at the earliest possible stages, when treatment can be most successful.

The EarlyCDTLung test can also be used in conjunction with diagnostic imaging such as x-ray or CT scan, to further assess the risk of lung cancer being present where indeterminate lung nodules have been detected but which may or may not be a sign of cancer.

This is not a genetic test for predisposition—a positive test may indicate the presence of the disease and an increased risk of malignancy. The test is sent to and performed in the CLIA-certified laboratory in Kansas City, USA. Currently, Early CDTLung is in use by more than 2000 physicians across the United States, and has aided in the detection of numerous early stage lung cancers. It is now also available in the UK. Article source: Oncimmune


Chemosensitivity Test (Personalized cytometric profiling)

Personalized cytometric profiling reveals which anti-cancer drugs are effective at killing each patient’s cancer cells and which agents are not effective. The most promising drug regimen can be selected for each cancer patient, increasing the odds for treatment success. At the same time, ineffective drugs are avoided.

This spares the patient needless exposure to harmful side effects from drugs that can’t possibly help them. Further, valuable treatment time is not wasted and the patient does not incur unnecessary costs from expensive but ineffective treatments. Source: Weisenthal Cancer Group

Learn more

Update: Chemosensitivity Tests can show up drugs designed for a cancer type other than yours that will actually treat you.


Chemosensitivity Tests available from:

R.G.C.C Group
Europe: email: info@rgcc-europe-nw.com
USA and Canada: email: info@rgccusa.com

Tests your sensitivity to both chemo drugs and natural substances.


Biofocus
Germany
Tests your sensitivity to both chemo drugs and natural substances.

Testing on samples from UK and Ireland.
Shipment of samples from these countries is possible by FedEx, DHL-Express or TNT. Usually, the shipment takes 1 day. Cooling is not necessary if samples are delivered during one day. If transit time exceeds one day, we recommend you send samples in a foam box with some cooling bags enclosed.


Therapy Select
Germany
Email: kontakt@therapyselect.de


Weisenthal Cancer Group
USA: email: mail@weisenthalcancer.com


Nagourney Cancer Institute
Nagourney Cancer Institute.
USA


Pierian Biosciences
USA


Helomics
USA


maintrac
Asia & Europe
Dr. Martin Burow

Email:info@dmb-diagnostics.de
Skype: Martin.Burow

Australia and New Zealand
Genostics Australia Pty Ltd

E drfluhrer@genostics.com.au
W www.genostics.com.au
F https://www.facebook.com/Genostics


Tests to Verify Treatment is Working

Peace of mind
There are a number of laboratory tests you can use to find out whether or not your treatment if working effectively. Having this information can save you precious time and give you the chance to change to a different treatment if the current one is not working. 

Learn more

Available Tests:

Oncotrace
Available from R.G.C.C Group
Europe email: info@rgcc-europe-nw.com
USA and Canada: email: info@rgccusa.com

Circulating Tumour Cells
CTCs are cancer cells which have broken away from the primary tumor and have entered the blood stream where they circulate and have the potential to generate metastatic disease. These cells can be isolated and identified and there is growing interest in their detection for the following purposes.

1. The early detection and diagnosis of new cancers
2  Monitoring existing cancers
3  Prognosis – providing information about the risk of recurrence of a current or old cancer

Source: R.G.C.C Group


CellSearch
Available from CellSearch. This is from the CellSearch website:

Changes in CTCs are predictive of disease progression among cancer patients receiving chemotherapy. The FDA-cleared CELLSEARCH® CTC Test aids in the monitoring of patients with metastatic breast, prostate*, or colorectal cancer.

Changes in CTCs are predictive of disease progression among cancer patients receiving chemotherapy. The FDA-cleared CELLSEARCH® CTC Test aids in the monitoring of patients with metastatic breast, prostate*, or colorectal cancer.

Serial testing for circulating tumor cells (CTCs) should be used in conjunction with other clinical methods for monitoring, such as imaging, lab tests, physical examination, and complete medical history to assess patient prognosis throughout the course of disease.

The AMAS Test
Available from: Oncolabinc

Physicians around the country are recommending and administering the AMAS test on a regular basis for patients at high risk for cancer, and for follow-up purposes on patients already diagnosed and/or treated for cancer. Article source: Oncolabinc

Note for patients outside the U.S
In an email, Oncolabinc said:
“We will do the AMAS test for European clients, but as stated below, it can be quite difficult. We have a partner in Germany who can run tests for those in Germany and Austria – patients can email us at info@oncolabinc.com requesting that information if they would like.”


The CA Profile Plus©
Available from: American Metabolic Laboratories (USA)

Treatment Monitoring
The Cancer Profile™© gives early warning signs, but it also can be used as a cancer marker test to monitor established, existing cancers. Retesting can demonstrate whether treatment regimens are working, and how they can be adjusted. The tests also are important to establish a benchmark prior to surgery. With a retest later, one can determine the surgery’s success in removing the tumor.

This also is borne out by research. For example, a study in the Journal of Tumor Marker Oncology (Luthgens M., et al., 1992, 7 [3]: 44) reports that men who had had their diseased prostates removed had distinctly lower levels of both PSA and HCG, compared with those patients with tumors remaining. Clearly, lower levels of these markers indicate a procedure’s effectiveness. Source: American Metabolic Laboratories


HCG Urine Immunoassay
Available from: Navarro Medical Clinic

Currently, many cancer patients take advantage of the diagnostic accuracy of the HCG test as an indicator of the effectiveness of their specific mode of therapy. Thousands of cancer survivors have used this test over the years to keep track of their treatment(s) success and check on the status of their remission. Article source: Navarro Medical Clinic


Maintrac
Available from: maintrac and Genostics
maintrac monitors the response to cancer therapies
Cancer cells can change during the course of disease. Monitoring these cells in their number and structure is important for early tailoring therapy and for selecting the most effective drugs. By determining dynamics in the number of tumor cells, the tumor activity can be monitored.

Benefits for patients:
maintrac helps to find a customized, personalized and effective therapy.

maintrac enables control of success of the applied therapy.

  1. Enumeration of the circulating tumor cells provides us with information whether the cells successfully are reduced by the therapy or increase despite therapy, i.e. the treatment is not effective.
  2. During maintenance therapy, maintrac helps to determine whether therapy is still effective.
  3. The drugs which destroy most of the circulating tumor cells can be tested even before chemotherapy. Thus the most effective therapy can be determined. Even naturopathic therapies can be monitored.

Article source: maintrac (company website)

See also: Current and potential use of MAINTRAC method for cancer diagnosis and prediction of metastasis.

maintrac Representation
Asia & Europe
Dr. Martin Burow
Email:info@dmb-diagnostics.de
Skype: Martin.Burow

maintrac Representation
Australia and New Zealand
E drfluhrer@genostics.com.au
F https://www.facebook.com/Genostics


Breast Cancer – Risk of Recurrence

A number of tests can guide treatment decisions and predict recurrence.

Learn more

Available Tests:
Oncotype DX® Breast Cancer Assay
Available from: Your oncologist in Ireland or Oncotypeiq

The Oncotypeiq website says: The Oncotype DX® Breast Cancer Assay can help physicians and patients decide on the best course of treatment. For invasive breast cancer, the Oncotype DX Breast Cancer Assay predicts chemotherapy benefit and the likelihood of distant breast cancer recurrence. The Oncotype DX Breast Cancer Assay for DCIS patients predicts the risk of local recurrence. 

MammaPrint
Available from: Agendia.com (through your physician).
The agendia.com website says: Agendia’s MammaPrint is a test which determines how aggressive a breast cancer tumour is. The MammaPrint result will enable your physician to determine what would be the best kind of treatment for you following your operation. 

Prosigna™
Available from: Nanostring Technologies (through your physician).
The Nanostring Technologies website says:

Prosigna provides a risk category and numerical score for assessment of the risk of distant recurrence of disease at 10 years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer.

The Prosigna Assay will be available for diagnostic use when ordered by a physician in the U.S. The Prosigna Assay has been CE-marked and is available for use by healthcare professionals in the European Union and other countries that recognize the CE Mark and in which Prosigna is registered. 

EndoPredict
Available from: Myriad Genetics Inc.  The endopredictusa.com website says:

EndoPredict is a 2nd generation breast cancer recurrence test for highly accurate assessment of 10-year risk of distant recurrence. Both gene expression with clinicopathological features are integrated into the EndoPredict test result to provide improved prognostic performance. EndoPredict is appropriate for women with:

  • early-stage invasive breast cancer (ref Filipits)
  • ER+, HER2− receptor status (ref Filipits)
  • node-negative (N0) and node-positive (N1)


Colon Cancer – Risk of Recurrence

The following test can be used to predict recurrence.
Oncotype DX® Colon Cancer Assay
Available from: Oncotypeiq. The company website says:
The Oncotype DX® Colon Cancer Assay quantifies recurrence risk in stage II and stage III colon cancer, beyond traditional qualitative measures. This enables an individualized approach to treatment planning. The Oncotype DX test measures a group of cancer genes in the tumor, providing a quantitative Recurrence Score® result beyond traditional measures so physicians and patients can have a more complete discussion of recurrence risk.

The Oncotype DX® Recurrence Score® result, when combined with mismatch repair status and T-stage, provides an individualized, quantitative and reproducible assessment of recurrence risk to help guide treatment decision-making for patients with stage II and stage III colon cancer.


Prostate Cancer – Risk of Recurrence

The following test can be used to predict recurrence.
Oncotype DX® Prostate Cancer Assay
Available from: Oncotypeiq. The company website says:
The Oncotype DX Genomic Prostate Score (GPS) assay is the only genomic assay designed for men with clinically low-risk cancer to help make treatment decisions at the time of diagnosis. The assay analyzes prostate cancer gene activity to predict disease aggressiveness.


Molecular Profiling

It is critically important to obtain a description of the type of cells that populate your tumor.

Learn more

Caris Life Sciences provides a range of tests. The following appears on its website:

How Molecular Profiling Works
Caris Molecular Intelligence performs thorough molecular testing on DNA, RNA and proteins to identify the biomarkers relevant for optimized treatment decisions in a patient’s tumor, and to compare the biomarkers with data from clinical studies around the world. This is a powerful asset to aid clinical decisions regarding individual cancer therapies. Caris Molecular Intelligence enables clinicians to:

  • Identify therapies with potential benefit
  • Identify therapies that may not have been considered
  • Determine drugs with potential lack of benefit (avoiding unnecessary toxicities and costs)
  • Match patients to clinical trials

See more at Caris Life Sciences


Test to Identify Nutritional Deficiencies

Vitamin deficiency occurs when you have a chronic lack of a specific vitamin. If the deficiency is caused by poor nutrition then it is called primary deficiency but if it’s caused by an underlying condition, it’s known as a secondary deficiency.

Secondary deficiencies can be caused by things such as malabsorption, chemotherapy, or diseases such as HIV.

Learn more

Glenville Nutrition (Ireland)
This is from their website:
Testing your levels of these key nutrients will allow your nutritionist to identify any gaps you may have and tailor their nutritional recommendations to meet your specific requirements.  This is useful for a wide range of health conditions and concerns.

From: Genova Diagnostics (USA)
The NutrEval FMV® is both a blood and urine test that evaluates over 125 biomarkers and assesses the body’s functional need for 40 antioxidants, vitamins, minerals, essential fatty acids, amino acids, digestive support, and other select nutrients. Personalized recommendations for nutrients are determined by using an algorithm based on the patient’s test findings. The NutrEval Plasma and NutrEval FMV (first morning void) differ based on which sample type is used to measure amino acids, plasma or urine.


Genomic Profiling

From: Foundation Medicine
Knowing the mutations in your cancer can help you and your doctor understand your treatment options and may help to personalise your treatment.


Biomeridian Stress Testing?

From: Vitality Centre Dublin
and Healthy Living Ireland (Co Laois)

Biomeridian testing is a noninvasive method used to assess the energy meridians (channels) of the body, and it can tell you:

  • The functional status of your meridians and their related organs, systems, or functions, by determining if they are stressed, balanced, or weakened, and by how much.
  • Which specific nutritional products will bring your unbalanced meridians back to balance.
  • If a product you have in hand will bring you to balance.
  • If you have specific sensitivities to foods, molds pollens, etc.
  • If you have spinal misalignments interfering with your meridian energy flow, and their location.

Toxic Metals Profile

From: Genova Diadnostics Europe
Increased exposure to toxic elements is generally reflected by levels in whole blood. The Genova Diagnostics Toxic Metals Profile shows levels of aluminum, arsenic, cadmium, lead, and mercury.


Methylation Panel (Test)

From: Genova Diagnostics
The Role of Methylation in Gene Expression
Source: Nature.com

Not all genes are active at all times. DNA methylation is one of several epigenetic mechanisms that cells use to control gene expression.

To date, a large amount of research on DNA methylation and disease has focused on cancer and tumor suppressor genes. Tumor suppressor genes are often silenced in cancer cells due to hypermethylation.

This study says micronutrients such as folate, choline, betaine, vitamin B12, and other B vitamins contribute to DNA methylation as methyl donors and co-factors. Therefore, the status of these nutrients might correlate with DNA methylation and offer potential preventive and therapeutic targets in pathological conditions such as cancer where aberrant DNA methylation is frequently observed.
*****
Some doctors recommend:
B Vitamins
(B6, Folate, Methylcobalamin)

(Riboflavin, Niacin, B6 and B12)
Choline
Betaine 
Creatine


Blood Tests to Detect Inflammation

From: Dublin Health Screening
and Bluehorizon Medicals

CRP are blood tests that detect inflammation. These are useful tests to help diagnose and monitor the activity of certain diseases.

Inflammation and blood proteins
If you have inflammation in a part of your body then extra protein is often released from the site of inflammation and circulates in the bloodstream. The CRP and ESR blood tests are commonly used to detect this increase in protein, and so are ‘markers’ of inflammation.


Glucose Test (HBA1C)

From: Blue Horizon Medicals
What is HbA1c?
Source: Health Services Executive

Haemoglobin A1c (HbA1c) is a minor component of total haemoglobin A (HbA), which is the oxygen-carrying protein that gives blood its red colour and is the predominant protein in red blood cells. HbA1c is formed when glucose binds to a specific part of the haemoglobin molecule following a complex chemical reaction. The HbA1c level is proportional to the weighted average blood glucose concentration in the preceding 6-8 weeks. So, the more glucose there is in the blood, the more glucose is attached to the haemoglobin and the greater the amount of HbA1c. Individuals without diabetes usually have HbA1c levels that are less than 6%.


Oxidized LDL Panel Blood Test

From: Life Extension
Oxidized low-density lipoprotein (oxLDL)

This study found:

  • OxLDL is a key metabolic link between obesity and cancer
  • OxLDL is an inducer of carcinogenesis
  • OxLDL promotes cancer proliferation, stimulates epithelial-to-mesenchymal transition and metastasis
  • OxLDL adversely affects chemosensitivity
  • OxLDL and its receptors are promising targets in cancer treatment

Hereditary Cancer Tests

The tests listed below can help assess your susceptibility to developing a cancer resulting from inherited genes.

First, a word about Epigenetics 
Testing positive for faulty genes does not necessarily mean that cancer will develop or progress. This is because of the new understanding of Epigenetics.

Learn more

Basically, Epigenetics influence which genes are activated and which ones are silenced. Epigenetic modifications are influenced by the environment – such as diet, lifestyle, stress factors etc.

The world’s foremost expert in Epigenetics is Prof. Bruce Lipton. His website explains Epigenetics in simple language we can all understand. It includes the following:

What about genetic predispositions to getting the disease? “It used to be that we thought a mutant gene caused cancer,” Lipton admitted, “but with epigenetics, all of that has changed.” Continue reading at BruceLipton.com


Genetic Predisposition Test

Available from: EasyDNA.ie
Have you ever wondered if the cancer that affected your grandfather could similarly affect you? Or whether the predominance of Alzheimer’s on your mother’s side of the family has been passed on through your genes? Genetic health predisposition testing could provide these answers and many more. Source: EasyDNA.ie


Hereditary Cancer Test

Available from: Color Genomics Inc.

Color’s Hereditary Cancer Test analyzes relevant genes for mutations that could increase your risk for breast, colorectal, melanoma, ovarian, pancreatic, prostate*, stomach, and uterine cancers.

BRCA Test
Color’s BRCA Test analyzes the BRCA1 and BRCA2 genes for mutations that can increase your risk for hereditary breast, ovarian, and other cancers. Mutations in BRCA1 and BRCA2 genes are the most common cause of hereditary breast and ovarian cancer.

Risk for women
BRCA1 mutation can increase a woman’s chance of breast cancer up to 81% and ovarian cancer up to 54% by age 80.

BRCA2 mutation can increase a woman’s chance of breast cancer up to 74% and ovarian cancer up to 12% by age 70.

Mutations in the BRCA1 and BRCA2 can also increase a woman’s chances of melanoma and pancreatic cancer.

Risk for men
Mutations in the BRCA1 and BRCA2 gene can also increase a man’s chances of male breast, melanoma, pancreatic, and prostate cancer.

Also, men are just as likely to have BRCA1 and BRCA2 mutations as women, and they are just as likely to pass them onto their children.
Source: Color.com


Counsyl Reliant Cancer Screen

Available from: Counsyl Inc.

If you have a personal or family history of cancer, find out your chances of developing breast, ovarian, colon, and other cancers.

Some of the genes we inherit from our parents are meant to protect us from certain cancers. Occasionally, we’ll inherit an irregular version of one of these genes, called a mutation. The Reliant Cancer Screen can look for irregularities in up to 36 genes that could mean you’re more susceptible to developing one of these cancers at some point in your life.
Source: Counsyl.com


Invitae Multi-Cancer Panel

Available from: Invitae Corporation

Genetic testing for 80 genes that are associated with hereditary cancers across eight major organ systems: breast and gyn, gastrointestinal, endocrine, genitourinary, skin, brain/nervous system, sarcoma, and hematologic.
Source: Invitae.com


Hereditary Cancer Genetic Tests

Tests available from: Pathway Genomics

This test is not for everyone; only high-risk patients should be tested
Most cancer is known as sporadic cancer. This cancer occurs in people who don’t have a family history or changes in their DNA that would increase their risk for cancer. On the other hand, hereditary DNA changes are present since birth and some of these changes can increase the risk of developing cancer. Our tests look for such cancer-causing changes (pathogenic variants) in certain genes.

Pathway Genomics genetic tests screen a number of known genes related to hereditary cancers. The goal of every test is to determine a patient’s risk of cancer. This knowledge can help your physician to develop the appropriate or preventative treatment plan for early detection. If the results of your test indicate an increased risk for cancer, your doctor may order tests like mammograms, colonoscopy and CT scans for any possible diagnosis and immediate intervention.
Source: Pathway Genomics

Please note:
1. cancerireland.ie does NOT benefit financially or otherwise from the inclusion of any product or service listed on this site.
2. The list of laboratories is not complete.

 

Please share this page to help others